// App-Quantinova.ai

: Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone

Researchers

Presenter

  • Jayanshu Jain

Principal Investigators

  • Ghena Khasawneh

  • Hamza Hashmi

  • Meera Mohan

  • Zahra Mahmoudjafari

  • Wei Cui

  • Joseph P. McGuirk

  • Leyla O. Shune

  • Nausheen Ahmed

  • Al-Ola Abdallah

  • Shebli Atrash

Medical Centers

  • The University of Kansas Medical Center, Kansas City, KS

  • US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS

  • Division of Hematology/Oncology, University of Kansas Medical Center, Kansas City, KS

  • Department of Hematology/Medical Oncology, Medical University of South Carolina, Charleston, SC

  • Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS

  • Medical College of Wisconsin, Milwaukee, WI

  • Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC

  • Faculty of Medicine, Jordan University of Science and Technology, Irbid, JOR

Locations

  • United States

  • Jordan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • daratumumab Intravenous

  • Melphalan

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved